Is Shield Therapeutics plc a better bet than AstraZeneca plc?

Does the small-cap potential of Shield Therapeutics plc (LON: STX) beat the blue chip reliability of AstraZeneca plc (LON: AZN) in the pharma stakes?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Do hares always beat tortoises? Are speedboats better than ocean liners? Are small-cap startup companies better than the established giants for growing your investment cash?

A lucrative startup?

The question must have crossed a few minds when reading today’s first-half results from Shield Therapeutics (LSE: STX), which floated on AIM as recently as February 2016.

Shield describes itself as a “specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals.” It reported its first revenues, of £240,000, from sales of its iron deficiency anaemia treatment Feraccru after it was approved in February. It’s a modestly-priced medication, but chief executive Carl Sterritt described its pricing agreements as attractive, and sales should also commence in Germany in October.

It’s hard to put any kind of valuation on Shield’s 159p shares at the moment, as there are no profits forecast yet, and consistent losses pencilled-in for this year and next. The firm did have £28.4m in cash on the books at 30 June but with pre-tax losses of £18m-£19m per year forecast for this year and next, there’s going to be some more fundraising needed before any profits start rolling in.

Where does this leave Shield Therapeutics as an investment possibility? It’s not a total blue-sky punt as it does have a marketable product and does actually have sales cash coming in, but other than that I see it as pretty much straight gambling if you invest right now — it looks like one of those companies that could make you a very big profit it it comes good, but could lose you your stake if it doesn’t.

Tried and trusted?

Are you better, then, to stick with an established blue chip pharmaceuticals company like AstraZeneca (LSE: AZN)? AstraZeneca was struggling against the expiry of patents and increased competition from generic drugs when Pascal Soriot took over as chief executive in October 2012.

Mr Soriot’s shake-up was severe, and it was always going to take a few years to rein in the firm’s falling earnings and return them to growth. I’d optimistically hoped for EPS growth by 2017, but that seems unlikely now, with falls of 2%-3% forecast for this year and next. Still, if we see EPS growth in 2018, that really won’t be a bad turnaround result at all.

I’m a little surprised that the price has spiked by a third since the middle of June to 5,164p. That’s taken the shares to a forward P/E multiple of 16.4 for 2017, though interim results on 28 July saw second-quarter falls across the board. It was all in line with expectations, mind, and there’s really nothing new that wasn’t known six months ago.

I suspect the price recovery is simply down to investors re-appraising the value of good old safe and solid shares like our big pharmaceuticals players, partly in the sobering light of the EU referendum result. And they’re realising that P/E ratings of around 16 or so aren’t at all stretching for dependable investments providing dividend yields in excess of 4% and which should be generating profits for decades to come.

At least, that’s the way I see AstraZeneca, and it would nice to think the market does too.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 super-safe dividend shares I’d buy to target a £1,380 passive income!

Looking to maximise your chances of making a large passive income? These FTSE 100 and FTSE 250 dividend shares might…

Read more »

Investing Articles

I’ve just made a huge decision about my Scottish Mortgage shares!

Harvey Jones has done pretty well after buying Scottish Mortgage shares a year ago but the closer he examines the…

Read more »

Investing Articles

These top passive income stocks all go ex-dividend in October!

Paul Summers has been running the rule on some brilliant passive income stocks, all of which have ex-dividend deadlines coming…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing For Beginners

2 Warren Buffett-type stocks in the UK’s FTSE 100 index worth a look today

Warren Buffett likes to invest in high-quality companies. He also likes to buy when valuations are attractive and he can…

Read more »

artificial intelligence investing algorithms
Growth Shares

The next industrial revolution has begun. Here are 3 growth stocks at its heart

Edward Sheldon believes these three growth stocks will do well as the AI industry grows and the world becomes more…

Read more »

Investing Articles

Given the current economic climate, is there value to be found in UK penny stocks?

Our writer evaluates the prospects of two promising penny stocks on the London Stock Exchange. They each have a compelling…

Read more »

Investing Articles

With yields at 9%+, I expect even more from these FTSE 100 dividend stocks

I'd thought FTSE 100 yields might be declining by now, as the stock market starts to gain. Can these big…

Read more »

A young black man makes the symbol of a peace sign with two fingers
Investing Articles

2 risky shares for investors to consider buying

It’s important to consider what could go wrong when working out which shares to buy. But sometimes the potential rewards…

Read more »